Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 4/20 | 0.53 |
| ▸ | PARP1 | P09874 | 3/20 | 0.50 |
| ▸ | KCNMA1 | Q12791 | 7/20 | 0.48 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PYGM | P11217 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24063492 | 0.89 | PDE9A (0.65) | PDE9APARP1KCNMA1KDM4E | |
| SCHEMBL24276341 | 0.89 | PDE9A (0.50) | PDE9APARP1KCNMA1GRM4MAPT | |
| SCHEMBL24063436 | 0.87 | PDE9A (0.51) | PDE9APARP1KCNMA1MAPTNPSR1 | |
| SCHEMBL24276323 | 0.82 | PDE9A (0.51) | PDE9APARP1KCNMA1KDM4E | |
| SCHEMBL6682463 | 0.80 | KCNMA1 (0.57) | PDE9APARP1KCNMA1GRM4MAPT | |
| SCHEMBL24275690 | 0.80 | PDE9A (0.58) | PDE9APARP1MAPTMAP2K1NPSR1 | |
| SCHEMBL20870616 | 0.76 | KDM5A (0.59) | PDE9APARP1MAPTMAP2K1NPSR1 | |
| SCHEMBL20870085 | 0.75 | KCNMA1 (0.63) | PDE9APARP1KCNMA1KDM4E | |
| SCHEMBL4754780 | 0.75 | PDE9A (0.60) | PDE9APARP1KCNMA1KDM4E | |
| SCHEMBL22275015 | 0.75 | PDE9A (0.48) | PDE9APARP1KCNMA1GRM4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220089593-A1 | PDE9 INHIBITOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2022-03-24 | — | — | US | disclosed |
| EP-3915992-A1 | PDE9 INHIBITOR AND USE THEREOF | Transthera Sciences (Nanjing), Inc. (CN) | 2021-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089593-A1 | PDE9 INHIBITOR AND USE THEREOF | PDE9A, PDE12, PDE5A | PDE9A 1/4885PARP1 2794/4885KCNMA1 1919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.